Best strategy for post op pain with novalgin, paracetamol, ibuprofen, piritramid. What are the contraindications for each and when can the 2nd Dosis be given. Maximal daily dose
Reading File
Now I'll search the medical library for all four drugs in parallel.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching the Web
postoperative pain management novalgin paracetamol ibuprofen piritramide dosing contraindications
Now let me get the detailed piritramide section from Miller's and check dosing details for all drugs:
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading Web Page
https://www.compva.com/science/drug-therapy-in-pain-manageme…
I now have sufficient data to compile a comprehensive answer. Let me put this all together.
Post-Op Pain Management: Novalgin, Paracetamol, Ibuprofen & Piritramide
Overall Strategy: Descending Multimodal Analgesia
For postoperative pain, the WHO step ladder is applied in reverse - start strong, then step down as pain decreases. Non-opioid analgesics (Level 1) should always be combined with Level 2/3 agents. The goal is opioid-sparing - using piritramide only for moderate-severe pain while anchoring the regimen with the three non-opioids.
Typical descending approach:
- Day 0-1 (severe pain): Piritramide (IV/PCA) + Novalgin/Metamizole IV + Paracetamol IV/oral
- Day 1-3 (moderate pain): Novalgin + Paracetamol ± Ibuprofen (if tolerated), reduce/stop piritramide
- Day 3+ (mild pain): Ibuprofen + Paracetamol, as needed
Drug-by-Drug Reference
1. Novalgin (Metamizole / Dipyrone)
| Mechanism | Inhibits prostaglandin synthesis centrally + peripherally; particularly effective for visceral/colic pain; mild spasmolytic |
| Dose (adult) | 500 mg - 1000 mg per dose (commonly 1 g IV over 15 min) |
| Interval (next dose) | Every 6-8 hours (can be given every 6 h IV if needed) |
| Max daily dose | 4 g/day (4 × 1 g); some protocols allow up to 5 g/day under close monitoring |
| Onset | IV: 15-30 min; oral: 30-45 min |
| Duration | 4-8 hours |
Contraindications:
- Hematological diseases (bone marrow suppression, agranulocytosis risk - key concern)
- Bronchial asthma (especially analgesic-induced asthma / Samter's triad)
- Hypersensitivity to pyrazolones
- G6PD deficiency (hemolysis risk)
- Hepatic porphyria
- Pregnancy (especially 1st trimester and at term - risk of premature closure of ductus arteriosus)
- Children < 3 months / < 5 kg
- Severe hepatic or renal impairment
- Note: Banned in several countries (Scandinavia, Japan, USA) due to risk of agranulocytosis (~1:1,000,000). Patients should be informed of this risk. Particularly useful when NSAIDs are contraindicated (renal insufficiency, GI ulcers).
2. Paracetamol (Acetaminophen)
| Mechanism | Central COX inhibition + endocannabinoid system modulation; analgesic and antipyretic but NOT anti-inflammatory |
| Dose (adult) | 500 mg - 1000 mg per dose |
| Interval (next dose) | Every 4-6 hours (minimum 4 h between doses) |
| Max daily dose | 4 g/day in healthy adults; 2-3 g/day in hepatic impairment, chronic alcohol use, or low body weight (<50 kg) |
| Onset | IV: 5-10 min; oral: 30-60 min |
| Duration | 4-6 hours |
Contraindications:
- Severe hepatic impairment / acute hepatitis / decompensated cirrhosis (use with extreme caution)
- Hypersensitivity to paracetamol
- Caution: Chronic alcohol use (>3 drinks/day), malnutrition/anorexia (depleted glutathione stores), G6PD deficiency (relative)
- Not contraindicated in renal impairment or GI ulcer history - this makes it a valuable drug when NSAIDs are contraindicated
- Note: Paracetamol is safe in compensated cirrhosis at adjusted doses (2-2.6 g/day). Do NOT combine with other paracetamol-containing preparations (cold/flu remedies).
3. Ibuprofen
| Mechanism | Non-selective COX-1/COX-2 inhibitor - anti-inflammatory, analgesic, antipyretic |
| Dose (adult) | 400-800 mg per dose |
| Interval (next dose) | Every 6-8 hours (400 mg can be given every 4-6 h, 800 mg every 8 h) |
| Max daily dose | 2400 mg/day (prescription dose); 1200 mg/day for OTC use |
| Onset | Oral: 30-60 min; IV: 10-15 min |
| Duration | 4-8 hours |
Contraindications:
- Renal impairment (eGFR < 50 mL/min is a hard contraindication; causes renal hypoperfusion and can precipitate acute kidney injury - especially relevant post-op)
- Active GI ulcer / GI bleeding (COX-1 inhibition impairs mucosal protection)
- Severe heart failure (NYHA III-IV)
- Severe coronary artery disease / recent MI / history of atherothrombosis (PAD, stroke)
- Analgesic-induced asthma (NSAID-sensitive asthma) - cross-reacts with other NSAIDs
- Concurrent therapeutic anticoagulation (increased bleeding risk; weak relative contraindication)
- Coagulopathy / platelet dysfunction (reversible platelet inhibition - concern for surgical bleeding)
- Pregnancy (especially ≥ 20 weeks - premature ductus closure, oligohydramnios; avoid in 3rd trimester entirely)
- Post-op caution: Avoid in hypovolemia, post-major surgery with high bleeding risk, bone surgery where NSAIDs may impair fracture healing (controversial but considered)
- If patient is on low-dose ASA for cardiovascular protection: allow a 2-hour interval between ibuprofen and ASA (ibuprofen can block ASA's antiplatelet effect)
4. Piritramide
| Mechanism | Synthetic opioid (piperidine derivative), primarily mu-opioid receptor agonist |
| Potency | ~0.7 relative to morphine (i.e., 15 mg piritramide ≈ 10 mg morphine) |
| Dose (adult) | IM/IV bolus: 7.5-15 mg; PCA: typically 1.5-2 mg bolus, 10-15 min lockout; titration: 3.75-4.5 mg IV increments |
| Interval (next dose) | Bolus: Every 4-6 hours (IM/IV); PCA lockout 10-15 min |
| Max daily dose | No fixed absolute maximum - titrate to effect; typical range 30-60 mg/day in PCA; individual doses not to exceed 15 mg IV |
| Onset | IV: 1-5 min; IM: 15-30 min |
| Duration | 4-6 hours per dose; slow elimination - accumulation risk with renal impairment |
Contraindications:
- Respiratory depression / severe COPD / respiratory failure (all opioids)
- Concurrent MAO inhibitor use (risk of serotonergic crisis)
- Ileus / raised intracranial pressure (relative)
- Severe hepatic impairment (reduced metabolism)
- Severe renal impairment (slower elimination - dose reduction required)
- Hypersensitivity to piritramide
- Alcohol/sedative intoxication
- Not recommended as first-line for mild pain (reserve for moderate-severe postoperative pain)
- Common side effects: Nausea/vomiting, sedation, respiratory depression, pruritus, urinary retention, ileus - same profile as morphine but reportedly slightly less hemodynamic instability
Combination Timing Strategy (Practical Example)
Staggered approach for continuous pain coverage (Day 1 post-op):
| Time | Drug |
|---|---|
| 06:00 | Paracetamol 1 g IV/oral |
| 08:00 | Novalgin 1 g IV |
| 12:00 | Paracetamol 1 g + Ibuprofen 400 mg |
| 14:00 | Novalgin 1 g IV |
| 18:00 | Paracetamol 1 g |
| 20:00 | Novalgin 1 g + Ibuprofen 400 mg |
| 00:00 | Paracetamol 1 g |
| PRN | Piritramide 7.5 mg IV for NRS ≥ 5, max every 4-6 h |
This stays within: Paracetamol 4 g, Novalgin 4 g, Ibuprofen 800 mg (conservative), and uses piritramide only as rescue.
Quick Comparison Summary
| Drug | Max Daily Dose | Dosing Interval | Key Contraindication |
|---|---|---|---|
| Novalgin | 4 g | Every 6-8 h | Hematological disease, asthma |
| Paracetamol | 4 g (2.6 g if liver disease) | Every 4-6 h | Hepatic failure |
| Ibuprofen | 2400 mg | Every 6-8 h | Renal impairment, GI ulcer, heart failure |
| Piritramide | ~60 mg (titrate) | Every 4-6 h (bolus) | Respiratory depression, MAOI use |
Key principle: Novalgin is particularly valuable when NSAIDs (ibuprofen) are contraindicated due to renal or GI issues. Paracetamol is safe in renal impairment. Piritramide should be combined with - not replace - the non-opioids to minimize opioid dose and side effects.
Sources: Miller's Anesthesia 10e (Piritramide section, p.2865); Barash Clinical Anesthesia 9e; Schwartz's Principles of Surgery 11e; compva.com drug therapy in pain management; postoperative analgesia routes review - PMC
85 year old patient arrhythmia after anesthesia but in sinus rhythm. What can be the cause? Indications for magnesium in anesthesia
Postoperative arrhythmias in the elderly are common and multifactorial - the main causes include electrolyte disturbances (hypokalemia, hypomagnesemia), hypoxia, hypercarbia, pain, hypothermia, and the direct effects of anesthetic agents. "In sinus rhythm" suggests the arrhythmia is sinus-based (sinus tachycardia, bradycardia, or sinus arrhythmia) rather than ectopic - though it could also mean they have returned to sinus after a transient arrhythmia.
Searching sources...
Finding Sources
Finding Sources
Searching the Web
postoperative arrhythmia causes elderly sinus rhythm anesthesia magnesium indications perioperative
Good results. Now let me pull the detailed textbook sections on arrhythmia causes and magnesium in anesthesia:
Reading File
Reading File
Finding Sources
Finding Sources
Excellent data. Let me get the magnesium indications in anesthesia section and the arrhythmia causes table:
Finding Sources
Finding Sources
Reading File
Now let me get the full magnesium indications in anesthesia from Morgan & Mikhail and Miller's:
Reading File
Finding Sources
I now have comprehensive data to deliver a thorough answer.
Post-Anesthesia Arrhythmia in an 85-Year-Old & Magnesium in Anesthesia
Part 1: Causes of Post-Anesthesia Arrhythmia in an 85-Year-Old (in Sinus Rhythm)
"In sinus rhythm" tells you the SA node is driving - but the rhythm can still be abnormal. This includes sinus tachycardia, sinus bradycardia, sinus arrhythmia with frequent PVCs/PACs, or a patient who briefly had a non-sinus arrhythmia and has returned to sinus. All these require systematic evaluation.
Why the Elderly Are Particularly Vulnerable
Age-related structural changes (atrial dilatation, fibrosis, reduced conduction velocity, stiff ventricles) lower the threshold for arrhythmia. The odds ratio for postoperative AF increases 1.51-fold per decade of age - at 85, any additional trigger easily tips the balance. (Miller's Anesthesia 10e, p.7496)
Systematic Causes - the "6 H + 6 T + Age" Framework
Metabolic / Electrolyte (most common, most correctable)
| Disturbance | Arrhythmia Risk |
|---|---|
| Hypokalemia | K+ < 3.5 mmol/L is a predictor of serious perioperative arrhythmia and POAF; catecholamine release during surgery drives K+ into cells, acutely dropping serum levels |
| Hypomagnesemia | Mg²+ drops frequently after major surgery; low levels correlate with increased arrhythmia incidence; cofactor for Na/K-ATPase - without Mg, you cannot correct K |
| Hypocalcemia | Prolongs QT, increases myocardial irritability |
| Hypophosphatemia | Muscle weakness + arrhythmia, especially post-major surgery |
Clinical pearl: You cannot fix hypokalemia without also repleting magnesium - Mg²+ is required for K+ reabsorption in the renal tubule and for Na/K-ATPase function.
Respiratory Causes
- Hypoxemia - reduced O2 delivery to myocardium; triggers catecholamine surge; sinus tachycardia, PVCs, AF
- Hypercarbia (CO2 retention) - causes sympathetic activation and acidosis-driven arrhythmia; common post-op in elderly with reduced respiratory reserve, residual opioids, or splinting from pain
- Residual neuromuscular blockade - leads to hypoventilation, hypoxia, hypercarbia
Hemodynamic / Cardiac Causes
- Pain / catecholamine surge - increases myocardial oxygen demand; sinus tachycardia and PVCs (PVCs after intubation/pain typically resolve with analgesia)
- Hypotension / hypovolemia - reflex tachycardia; ischemia if coronary artery disease present
- Myocardial ischemia or infarction - silent MI is more common in elderly post-op; any new arrhythmia requires ECG + troponins
- Pulmonary embolism - causes acute right heart strain + sinus tachycardia; high index of suspicion post-op
- Pericardial inflammation - after cardiac/thoracic procedures
Autonomic / Drug-Related Causes
- Residual anesthetic agents - volatile anesthetics sensitize the myocardium to catecholamines; halothane classically, but sevoflurane and desflurane also relevant
- QT-prolonging drugs given in PACU: ondansetron/dolasetron (5-HT3 antagonists), droperidol, haloperidol, albuterol, methadone, amiodarone - risk of torsades de pointes
- Beta blocker / ACEI withdrawal - abrupt perioperative withdrawal significantly increases POAF risk
- Digoxin toxicity - especially in elderly with even mild acute kidney injury post-op
- Neostigmine - can cause sinus bradycardia if atropine dose is insufficient
- Succinylcholine - bradycardia (especially with repeat dosing)
Structural / Cardiac Risk Factors
- Pre-existing cardiac disease - coronary artery disease, valvular disease, prior AF
- Atrial dilatation - age-related; disrupts atrial electrical coupling
- Left ventricular hypertrophy - common in elderly hypertensives; increases vulnerability
Temperature
- Hypothermia - core temperature < 35°C slows conduction, prolongs QT, causes shivering (sinus tachycardia), and can precipitate AF and VF
- Elderly patients cool faster and rewarm slower; PACU temperature management is essential
Other Perioperative Factors
- Fluid shifts - changes atrial size/stretch, directly triggering atrial arrhythmias
- Pericardial/atrial irritation - post-thoracic or cardiac surgery
- Increased sympathetic tone - pain, anxiety, emergence agitation in a confused elderly patient
- Sepsis - any new arrhythmia should prompt search for infection, especially post-abdominal surgery
Diagnostic Approach (Immediate)
- 12-lead ECG - compare with pre-op; look for ischemia, QT changes, conduction abnormalities
- SpO2, ABG - rule out hypoxia/hypercarbia
- Temperature - core temp
- Electrolytes - K+, Mg²+, Ca²+, glucose
- Troponin - rule out silent MI (especially in elderly)
- Chest X-ray - pulmonary edema, pneumothorax, pleural effusion
- Medication review - QT-prolonging agents, withdrawal of chronic cardiac meds
"Treatment relies on identifying and correcting the underlying cause (i.e., hypoxemia or electrolyte abnormalities) of the arrhythmia." - Miller's Anesthesia 10e, p.11611
Part 2: Indications for Magnesium in Anesthesia
Magnesium is one of the most versatile drugs in the anesthesiologist's toolkit, with actions across multiple domains:
Mechanism of Action in Anesthesia
Magnesium is a physiological calcium antagonist and NMDA receptor antagonist. Its key perioperative effects:
- Decreases anesthetic requirements (reduces MAC)
- Attenuates nociception via NMDA receptor blockade
- Blunts the cardiovascular response to laryngoscopy and intubation
- Potentiates neuromuscular blockade
- Moderates catecholamine release from the adrenal medulla
- Slows sinoatrial node activity and prolongs AV conduction
- Stabilizes excitable membranes
(Morgan & Mikhail's Clinical Anesthesiology 7e, p.2191)
Indications by Category
1. Cardiac Arrhythmia (PROVEN indications)
| Indication | Dose |
|---|---|
| Torsades de pointes (drug-induced or long QT) | 1-2 g IV over 5 min, may repeat - FIRST-LINE treatment |
| Digoxin-induced ventricular tachyarrhythmias | 1-2 g IV |
| Multifocal atrial tachycardia (MAT) | 1-2 g IV |
| Refractory ventricular fibrillation | 2 g IV (reasonable if refractory to defibrillation) |
| Perioperative AF prophylaxis | 1-2 g IV perioperatively (reduces incidence by ~50% in cardiac surgery) |
| Postoperative arrhythmia treatment (AF, SVT, ventricular ectopy) | Adjunct to beta blockers/amiodarone |
"Treatment with 1 to 2 g of magnesium IV over 5 minutes should be initiated and potentially repeated, if necessary, in the event of torsades de pointes." - Miller's Anesthesia 10e, p.11610
2. Obstetrics / Preeclampsia
- Preeclampsia/Eclampsia seizure prophylaxis and treatment - FIRST-LINE; more effective than phenytoin for eclampsia
- Loading dose: 4-6 g IV over 15-20 min
- Maintenance: 1-2 g/h IV infusion
- Fetal neuroprotection before preterm delivery < 32 weeks (reduces cerebral palsy)
- Tocolysis for preterm labor (second-line)
3. Multimodal Analgesia / Opioid Sparing
- Part of modern multimodal analgesia protocols; NMDA antagonism reduces central sensitization and opioid requirements
- Reduces postoperative opioid consumption
- Typical dose: 30-50 mg/kg IV intraoperatively
4. Hemodynamic Stability
- Blunts hypertensive response to laryngoscopy and intubation (especially useful in hypertensive patients, aortic surgery, intracranial procedures)
- Dose: 40-60 mg/kg before induction or 2 g bolus before laryngoscopy
5. Bronchospasm
- IV magnesium relaxes airway smooth muscle via calcium antagonism
- Used as adjunct in intraoperative/perioperative bronchospasm refractory to standard treatment
- Dose: 25-50 mg/kg IV
6. Neuromuscular Blockade Potentiation
- Magnesium potentiates both depolarizing and non-depolarizing NMBs (impairs Ca²+-mediated acetylcholine release at neuromuscular junction)
- Dose reduction of NMBs required in patients on magnesium infusions (e.g., preeclampsia patients)
- Monitor neuromuscular function carefully
7. Treatment of Magnesium Deficiency
- Hypomagnesemia is common post-op (frequent measurement recommended), especially after cardiac surgery, diuretic use, alcoholism, prolonged ICU stay
Magnesium Dosing Summary (Adult)
| Indication | Dose |
|---|---|
| Torsades de pointes | 1-2 g IV over 5 min (repeat if needed) |
| Eclampsia | 4-6 g IV load, then 1-2 g/h |
| Preop laryngoscopy blunting | 40-60 mg/kg or 2 g IV |
| Periop arrhythmia prophylaxis | 2 g IV |
| Multimodal analgesia | 30-50 mg/kg intraop |
| Bronchospasm (adjunct) | 25-50 mg/kg IV |
Monitoring / Safety
- Normal serum level: 1.7-2.1 mEq/L
- Therapeutic range (eclampsia): 4-7 mEq/L
- Loss of patellar reflex: ~7-10 mEq/L (early toxicity warning sign)
- Respiratory depression: > 12 mEq/L
- Cardiac arrest: > 15 mEq/L
- Antidote: Calcium gluconate 1 g IV (10 mL of 10%)
- Use with caution / dose-reduce in renal impairment (primary excretion is renal)
- Patients on therapeutic magnesium (e.g., preeclampsia) need reduced NMB doses with careful TOF monitoring
Summary for your 85-year-old: Start with the basics - check O2 sat, ABG, electrolytes (K+ and Mg²+ first), temperature, 12-lead ECG, troponin. Most post-op arrhythmias in the elderly are driven by hypokalemia + hypomagnesemia + catecholamine surge from pain or emergence. Replace electrolytes first. If torsades is suspected or confirmed (polymorphic VT + prolonged QT), give 2 g MgSO4 IV over 5 min immediately.
Sources: Miller's Anesthesia 10e; Morgan & Mikhail's Clinical Anesthesiology 7e; Tintinalli's Emergency Medicine; magnesium in cardiovascular disease - J Clin Basic Cardiol; postoperative arrhythmias after cardiac surgery - PMC
Lidocaine intravenous indications in anesthesia
IV lidocaine in anesthesia is a remarkably versatile drug - it blunts airway reflexes, reduces opioid requirements, has anti-inflammatory properties, and treats ventricular arrhythmias. It's increasingly used as part of multimodal analgesia protocols.
Searching sources...
Finding Sources
Finding Sources
Searching the Web
intravenous lidocaine indications anesthesia perioperative multimodal analgesia dosing 2024
Good results. Now let me pull the detailed textbook sections - the multimodal analgesia table from Barash and lidocaine-specific sections from Miller's:
Reading File
Finding Sources
Finding Sources
Finding Sources
Now let me get the Miller's detailed section on systemic lidocaine and the Fischer's Mastery section:
Reading File
Reading File
Reading File
Excellent - I now have comprehensive data from multiple authoritative sources. Here is the full answer:
Intravenous Lidocaine in Anesthesia - Indications, Dosing & Safety
Mechanism of Action
IV lidocaine acts through multiple simultaneous pathways, which explains its broad clinical utility:
- Voltage-gated Na+ channel blockade - primary mechanism; blocks ectopic neuronal firing and abnormal automaticity
- NMDA receptor antagonism (indirect, via PKC inhibition) - reduces central sensitization; key for neuropathic pain and opioid tolerance
- Voltage-gated Ca²+ and K+ channel modulation
- G protein-coupled receptor (GPCR) inhibition - especially Gαq11 subfamily
- Anti-inflammatory effects - inhibits leukocyte adhesion, cytokine release, and inflammatory signaling
- Glycinergic system modulation
"Systemic lidocaine displays analgesic, anti-inflammatory, and anti-hyperalgesic properties, which are mediated by inhibition of voltage-dependent sodium channels, NMDA receptors, and GPCRs." - Barash Clinical Anesthesia 9e
Indications in Anesthesia
1. Multimodal Analgesia / Opioid Sparing (Primary Use in Modern Anesthesia)
The most important perioperative indication. IV lidocaine is now a core component of ERAS (Enhanced Recovery After Surgery) protocols.
Evidence is strongest for:
- Abdominal surgery (open and laparoscopic) - reduces pain scores, opioid consumption, and length of stay
- Laparoscopic colectomy - attenuates postoperative ileus AND improves analgesia
- Colorectal surgery - reduces time to first bowel movement by an average of ~8 hours
- Thoracic surgery
- Prostatectomy
- Mastectomy
- Multilevel spine surgery
- Bariatric surgery - particularly valuable because these patients are more sensitive to opioid respiratory depression
Patient groups with most favorable risk-benefit balance:
- Opioid-tolerant / chronic pain patients (NMDA blockade helps with opioid-induced hyperalgesia)
- Patients at high risk from opioids: OSA, obesity, respiratory compromise
- Patients at risk for prolonged ileus
- Patients at risk for chronic postsurgical pain
(Barash 9e; Fischer's Mastery of Surgery 8e; IntechOpen review)
2. Attenuation of Laryngoscopy / Intubation Response
IV lidocaine blunts the sympathetic (hypertensive/tachycardic) and airway reflex response to laryngoscopy and intubation. Particularly useful in:
- Raised intracranial pressure (ICP) - prevents ICP spike from laryngoscopy
- Open eye injury / glaucoma / retinal detachment - prevents intraocular pressure (IOP) surge during intubation
- Severe hypertension or cardiovascular risk where the pressor response must be minimized
- Aortic/intracranial vascular surgery
Dose for this indication: 1-1.5 mg/kg IV, 2-3 minutes before laryngoscopy
"Intravenous lidocaine given, and extubation performed as soon as safely possible" - Miller's 10e (open eye surgery management)
3. Blunting of Extubation Response / Smooth Emergence
IV lidocaine suppresses airway reactivity during emergence and extubation, reducing:
- Coughing / bucking on the tube (dangerous in neurosurgery, eye surgery, ENT)
- Laryngospasm risk
- Breath-holding / desaturation at emergence
Dose: 1-1.5 mg/kg IV, 1-2 minutes before planned extubation
4. Ventricular Arrhythmia Treatment
Lidocaine is a Class IB antiarrhythmic (Na+ channel blocker, shortens the action potential). It acts selectively on diseased/ischemic tissue with high use-dependent block.
| Indication | Notes |
|---|---|
| Pulseless VT / VF | Alternative to amiodarone in ACLS when amiodarone unavailable or refractory; used when ROSC achieved after lidocaine was used |
| Stable ventricular tachycardia | Third-line after procainamide and amiodarone |
| Ventricular tachycardia storm | Used in combination with amiodarone |
| PVCs after intubation | When associated with ischemia or catecholamine surge |
| Digoxin-induced ventricular arrhythmias | Effective (does not affect digitalis effect on AV node) |
Important: Lidocaine does NOT affect atrial or AV junctional arrhythmias (minimal effect on atrial tissue at therapeutic doses). It is NOT used for SVT or AF.
Dose: Bolus 1-1.5 mg/kg IV, then infusion 1-4 mg/min (ACLS)
5. Neuropathic / Chronic Pain - IV Diagnostic Infusion
A single IV lidocaine infusion can:
- Serve as a diagnostic test to predict response to oral mexiletine (oral Na+ channel blocker)
- Provide pain relief in neuropathic conditions that may persist days to weeks beyond the drug's plasma half-life (mechanism unknown - possibly resets central sensitization)
- Used for: complex regional pain syndrome (CRPS), central neuropathic pain, postherpetic neuralgia, painful diabetic neuropathy, primary erythromelalgia
"Relief of preexisting neuropathic pain, both clinically and in animal models, can in some cases persist for days, weeks, or months after a single intravenous infusion of drug, far beyond the lifetime of the drug in vivo." - Miller's Anesthesia 10e
6. Prevention / Treatment of Postoperative Nausea and Vomiting (PONV)
IV lidocaine has a mild antiemetic effect, likely through its anti-inflammatory and glycinergic mechanisms. It is a secondary benefit rather than a primary indication.
7. Bronchospasm (Adjunct)
Topical lidocaine on the airway before intubation reduces bronchospasm. IV lidocaine can be used as an adjunct during intraoperative bronchospasm, though it is not a primary treatment.
8. Oncosurgery - Emerging Indication
Pre-clinical and early clinical data suggest IV lidocaine may reduce cancer recurrence through:
- Inhibition of tumor progression and metastasis
- Immune modulation (preservation of NK cell function)
- Anti-inflammatory effects reducing surgical stress response
One retrospective study (n=2,239) showed longer overall survival with IV lidocaine during pancreatic cancer surgery (HR 0.62). Not yet a proven clinical indication but an active area of research.
Dosing Summary
| Purpose | Bolus | Infusion | Duration |
|---|---|---|---|
| Multimodal analgesia (intraop) | 0.5-1.5 mg/kg over 10 min (ideal body weight, max 100-150 mg) | 1-1.5 mg/kg/h (max 120 mg/h) | Intraop + up to 24-48h postop |
| Laryngoscopy / extubation blunting | 1-1.5 mg/kg IV 2-3 min before | - | Single dose |
| Ventricular arrhythmia (ACLS) | 1-1.5 mg/kg IV push | 1-4 mg/min | Per ACLS protocol |
| Neuropathic pain infusion | 1-5 mg/kg over 20-60 min | - | Single session |
Target serum concentration for analgesia: 1-5 mcg/mL
Toxic concentration: > 5 mcg/mL (CNS and cardiac toxicity)
Contraindications to IV Lidocaine Infusion
| Contraindication | Reason |
|---|---|
| Cardiac arrhythmia / heart block | May worsen conduction; risk of complete block |
| Severe heart failure / very low EF | Reduced hepatic blood flow - impaired metabolism, accumulation |
| Coronary artery disease (severe) | Cardiac toxicity risk |
| Stokes-Adams syndrome | AV block |
| Seizure disorder | Lowers seizure threshold at toxic levels |
| Severe hepatic failure | Lidocaine is >90% hepatically metabolized (CYP1A2, CYP3A4) |
| Pregnancy | Relative contraindication |
| Weight < 40 kg | Avoid IV infusion |
| Concurrent regional anesthesia / epidural / nerve blocks / topical lidocaine patches | Additive LAST risk - do NOT combine |
| Electrolyte imbalance (severe) | Altered conduction |
LAST (Local Anesthetic Systemic Toxicity) - Key Safety Points
Early symptoms (CNS):
- Circumoral numbness, metallic taste
- Dizziness, tinnitus, visual disturbances
- Agitation, confusion
Progression:
- Seizures
- CNS depression, coma
Cardiovascular (later, more serious):
- Hypotension
- Heart block, wide QRS
- Life-threatening arrhythmias, cardiac arrest
Treatment:
- Stop lidocaine immediately
- Airway management, O2, BLS/ACLS
- Intralipid (20% lipid emulsion) 1.5 mL/kg IV bolus - definitive rescue treatment
- Avoid vasopressin, calcium channel blockers, beta blockers, and propofol in LAST management
Key Clinical Pearls
- Do NOT combine IV lidocaine infusion with any other local anesthetic delivery (epidural, nerve block, wound catheters, topical patches) - additive LAST risk
- Continuous ECG + SpO2 + blood pressure monitoring is mandatory during infusion
- Dose based on ideal body weight (actual body weight gives ~20% higher plasma concentrations)
- Effect on bowel motility (anti-ileus) is most consistent in visceral/abdominal surgery - evidence for other surgery types is weaker
- The infusion does NOT need to be stopped at a specific time before skin closure - this has no clinical significance
- Patients on CYP1A2/CYP3A4 inhibitors (azole antifungals, macrolides, diltiazem, verapamil, protease inhibitors) require dose reduction due to impaired metabolism
Sources: Miller's Anesthesia 10e; Barash Clinical Anesthesia 9e; Fischer's Mastery of Surgery 8e; Tintinalli's Emergency Medicine; MDPI perioperative lidocaine review; IntechOpen lidocaine consensus; ASRA lidocaine newsletter
This is a shared conversation. Sign in to Orris to start your own chat.